Flerie AB (FRA:1NP1) Change In Receivables: €0.39 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1NP1 Flerie AB FRA:1NP1
37 GF Score
Price €1.49
! 1 Warning Sign
View Full Analysis

What is Flerie AB Change In Receivables?

Flerie AB FRA:1NP1 -2.30% 37 Change In Receivables is €0.39 Mil as of Jun. 2026. GuruFocus rates FRA:1NP1 with a GF Score™ of 37/100. The stock has 1 warning sign investors should review.

Flerie AB's change in receivables for the quarter that ended in Jun. 2026 was €0.15 Mil. It means Flerie AB's Accounts Receivable declined by €0.15 Mil from Mar. 2026 to Jun. 2026 .

Flerie AB's change in receivables for the fiscal year that ended in Dec. 2025 was €-1.20 Mil. It means Flerie AB's Accounts Receivable increased by €1.20 Mil from Dec. 2024 to Dec. 2025 .

Flerie AB's Accounts Receivable for the quarter that ended in Jun. 2026 was €0.06 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Flerie AB's Days Sales Outstanding for the three months ended in Jun. 2026 was 49.08.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Flerie AB's liquidation value for the three months ended in Jun. 2026 was €26.49 Mil.

Flerie AB  (FRA:1NP1) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Flerie AB's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.064/0.119*91
=49.08

2. In Ben Graham's calculation of liquidation value, Flerie AB's accounts receivable are only considered to be worth 75% of book value:

Flerie AB's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=27.886-1.441+0.75 * 0.064+0.5 * 0
=26.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Flerie AB Change In Receivables Related Terms

Flerie AB Change In Receivables Historical Data

* Premium members only.

The historical data trend for Flerie AB's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Flerie AB Change In Receivables Chart

Flerie AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.04 1.11 0.39 1.12 -1.20

Flerie AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.44 -0.15 -0.27 0.65 0.15
FRA:1NP1
37GF Score
Flerie AB FRA:1NP1
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Flerie AB Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of €0.39 Mil mean?
Flerie AB (FRA:1NP1) has a Change In Receivables of €0.39 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Flerie AB and its competitors.
Is Flerie AB's Change In Receivables too high?
Flerie AB's current Change In Receivables is €0.39 Mil. Overall, Flerie AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Flerie AB's Change In Receivables compare to VRTX and REGN?
Flerie AB's Change In Receivables of €0.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Flerie AB and its competitors. Flerie AB's current Change In Receivables is €0.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Flerie AB stock overvalued right now?
Flerie AB (FRA:1NP1) has a current Change In Receivables of €0.39 Mil. The current Change In Receivables is €0.39 Mil. Flerie AB's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Flerie AB (FRA:1NP1), the current Change In Receivables is €0.39 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Flerie AB Business Description

Other Exchanges FLERIE:Sweden1NP1:Germany
Address Skeppsbron 16, Stockholm, SWE, 111 30
Flerie AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The portfolio of the company includes Immuno-Oncology, metabolic diseases, and biologics development and manufacturing organizations. It operates in two segments The Product Development segment, and The Commercial Growth segment. The Product Development segment consists of early and mid-stage biotech and pharma companies advancing their products and technologies toward clinical proofof-concept and marketing approvals. The Commercial Growth segment consists of companies already selling products or services, showcasing their ability to generate increasing revenues ahead of reaching sustainable profitability.
37GF Score

Get the complete analysis for FRA:1NP1

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.49
Price